Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer

Journal of Clinical Oncology

Volumn 18, Issue 12, 2000, Pages 2419-2426

  Rini, Brian I ^a   Vogelzang, Nicholas J ^a   Dumas, Mary C ^a   Wade III, James L ^a   Taber, David A ^a   Stadler, Walter M ^a  

^a University of Chicago   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; GEMCITABINE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; FATIGUE; FEMALE; HUMAN; KIDNEY CARCINOMA; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME; VOMITING;

EID: 0034046892     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.12.2419     Document Type: Article

References (25)

1. Vogelzang NJ, Stadler WM: Kidney cancer. Lancet 352:1691-1696, 1998
2. Hawkins MJ: Immunotherapy with high-dose interleukin 2, in Vogelzang NJ, Scardino PT, Shipley WU, et al (eds): Comprehensive Textbook of Genitourinary Oncology. Baltimore, MD, Williams and Wilkens, 1996, pp242-247
3. Atkins MB, Mier JW: Therapeutic Application of Interleukin-2. New York, NY, Marcell Dekker, Inc, 1993
4. Rosenberg SA, Yang SL, Topalian JL, et al: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA 271:907-913, 1994
5. Schilsky RL: Antimetabolites, in Perry MC (ed): The Chemotherapy Sourcebook. Philadelphia, PA, William and Wilkins, 1992, pp301-317
6. Yagoda A, Abi-Rached B, Petrylak D: Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol 22:42-60, 1995
7. Hartmann JT, Bokemeyer C: Chemotherapy for renal carcinoma. Anticancer Res 19:1541-1543, 1999
8. Kish JA, Wolf M, Crawford ED, et al: Evaluation of low dose continuous infusion 5-fluorouracil in patients with advanced and recurrent renal carcinoma: A Southwest Oncology Group Study. Cancer 74:916-919, 1994
9. Heineman V, Xu YZ, Chubb S, et al: Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2,2-difluorodeoxycytidine. Mol Pharmacol 38:567-572, 1990
10. Baker CH, Banzon J, Bollinger JM, et al: 2-deoxy-2-methylenecytidine and 2-deoxy-2,2-difluorocytidine 5-diphosphates: Potent mechanism-based inhibitors of ribonucleotide reductase. J Med Chem 34:1879-1884, 1991
11. Abbruzzese JL, Grunewald F, Weeks EA, et al: A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9:491-498, 1991
12. Ren Q, Kao V, Grem JL: Cytotoxicity and DNA fragmentation associated with sequential gemcitabine and d5-fluoro-2-deoxyuridine in HT-29 colon cancer cells. Clin Cancer Res 4:2811-2818, 1998
13. Bertucci D, Mani S, Vogelzang NJ, et al: Phase I trial of continuous infusion 5-fluorouracil (FU) and weekly gemcitabine (dFdC): Updated results. Proc Am Soc Clin Oncol 18:203a, 1999 (abstr 782)
14. Shurin MR, Esche C, Lotze MT: FLT3: Receptor and ligand - Biology and potential clinical application. Cytokine Growth Factor Rev 9:37-48, 1998
15. Rini BI, Stadler WM, Spielberger RT, et al: Granulocyte macrophage-colony stimulating factor in metastatic renal cell carcinoma: A phase II trial. Cancer 82:1352-1358, 1998
16. Stadler WM, Vogelzang NJ, Hoffman PC, et al: CI-980 in renal cell and non-small cell lung cancer: Multi-institutional trials from the University of Chicago Phase II Consortium. Cancer Therapeutics 1:318-320, 1998
17. Stadler WM, Vogelzang NJ, Amato R, et al: Flavopiridol, a novel cyclin dependent kinase inhibitor, in metastatic renal cancer: A University of Chicago Phase II Consortium study. J Clin Oncol 18:371-375, 2000
18. Chapman AE, Goldstein LJ: Multiple drug resistance: Biologic basis and clinical significance in renal cell carcinoma. Semin Oncol 22:17-28, 1995
19. Rainey JM, Rinaldi DA, Lormand NA: A phase I trial of gemcitabine (GEM) and infusional 5-fluorouracil (FU) in patients with refractory solid tumors. Proc Am Soc Clin Oncol 18:225a. 1999 (abstr 865)
20. Williamson SK, Iqbal M, Vogel S: Phase I/II trial of weekly gemcitabine and low dose continuous infusion 5-FU in patients with advanced malignancies. Proc Am Soc Clin Oncol 18:232a, 1999 (abstr 895)
21. Hidalgo M, Castellano D, Paz-Ares L, et al: Phase I/II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. J Clin Oncol 17:585-592, 1999
22. De Mulder PH, Weissbach L, Jakse G, et al: Gemcitabine: A phase II study in patients with advanced renal cancer. Cancer Chemother Pharmacol 37:491-495, 1996
23. Jolivet J, Giroux L, Laurin S, et al: Microangiopathic hemolytic anemia, renal failure and noncardiogenic pulmonary edema: A chemotherapy-induced syndrome. Cancer Teat Rep 67:429-434, 1983
24. Okamoto T, Noguchi Y, Yoshikawa T, et al: Chemotherapy-induced thrombotic occlusion of mesenteric arteries-case report and review of the literature. Gan To Kagaku Ryoho 21:1279-1282, 1994
25. Flombaum CD, Mouradian JA, Casper ES, et al: Thrombotic microangiopathy as a complication of long-term therapy with gemcitabine. Am J Kidney Dis 33:555-562, 1999